Immunome Inc's stock price fell by 10.22% as it crossed below the 5-day SMA, reflecting a challenging trading environment.
This decline comes amid the company's announcement of an 18.625 million share offering priced at $21.50, raising approximately $400 million to support its cancer therapy development. The offering, managed by notable underwriters, indicates strong market confidence but may have led to short-term selling pressure as investors react to dilution concerns.
The implications of this fundraising are significant, as it enhances Immunome's financial strength to accelerate clinical projects, particularly following the positive Phase 3 trial results for its drug varegacestat. However, the immediate market reaction suggests a cautious approach from investors amid the share offering.
Wall Street analysts forecast IMNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMNM is 33.20 USD with a low forecast of 21.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast IMNM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMNM is 33.20 USD with a low forecast of 21.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Buy
0 Hold
0 Sell
Strong Buy
Current: 26.140
Low
21.00
Averages
33.20
High
40.00
Current: 26.140
Low
21.00
Averages
33.20
High
40.00
Guggenheim
Buy
upgrade
$25 -> $35
2025-12-16
Reason
Guggenheim
Price Target
$25 -> $35
AI Analysis
2025-12-16
upgrade
Buy
Reason
Guggenheim raised the firm's price target on Immunome to $35 from $25 and keeps a Buy rating on the shares after the company reported positive top-line Phase 3 trial results for varegacestat. The firm believes approval likelihood is high and that varegacestat is well-positioned to capture the majority share in the a potential $1B-$2B DT market in the U.S.
Evercore ISI
NULL
to
Outperform
upgrade
$18 -> $40
2025-12-16
Reason
Evercore ISI
Price Target
$18 -> $40
2025-12-16
upgrade
NULL
to
Outperform
Reason
Evercore ISI raised the firm's price target on Immunome to $40 from $18 and keeps an Outperform rating on the shares. The "overwhelmingly positive" results from the RINGSIDE trial bolstered confidence in varegacestat's potential as a leading treatment for desmoid tumors, the analyst tells investors.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMNM
Unlock Now
Lake Street
Buy
maintain
$22 -> $32
2025-12-16
Reason
Lake Street
Price Target
$22 -> $32
2025-12-16
maintain
Buy
Reason
Lake Street raised the firm's price target on Immunome to $32 from $22 and keeps a Buy rating on the shares after the RINGSIDE trial reached high levels of statistical significance on its key efficacy endpoints. These data "appear to be a win on all fronts and are likely to propel varegacestat to the class leader shortly after launch," the analyst tells investors.
Leerink
Outperform
upgrade
$38 -> $40
2025-12-15
Reason
Leerink
Price Target
$38 -> $40
2025-12-15
upgrade
Outperform
Reason
Leerink raised the firm's price target on Immunome to $40 from $38 and keeps an Outperform rating on the shares. Varegacstat Phase 3 success has moved the firm's investment thesis ringside for commercial launch and execution, where management has as strong track record of success, and opens the door for a pipeline unveiling, the analyst tells investors in a research note. The firm added that while longer-term treatment duration for the varegacestat class remains an outstanding commercial question, it believes the new data unlock a roughly $780M peak revenue opportunity.
About IMNM
Immunome, Inc. is a clinical-stage targeted oncology company, which is focused on developing first-in-class and targeted therapies designed to improve outcomes for cancer patients. The Company is engaged in advancing an innovative portfolio of therapeutics in the design, development, and commercialization of targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Its advanced pipeline programs are varegacestat, a gamma secretase inhibitor which is in a Phase III trial for the treatment of desmoid tumors; IM-1021, an ROR1-targeted ADC which is in a Phase I trial, and IM-3050, a FAP-targeted radioligand. The Company's pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors. IM-1617 is a potential first-in-class ADC that targets an undisclosed receptor that is expressed in a range of solid tumors, including colorectal cancer and ovarian cancers.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
